• LAST PRICE
    12.7600
  • TODAY'S CHANGE (%)
    Trending Up0.3600 (2.9032%)
  • Bid / Lots
    12.1000/ 1
  • Ask / Lots
    0.0000/ 0
  • Open / Previous Close
    12.4000 / 12.4000
  • Day Range
    Low 12.1550
    High 13.0000
  • 52 Week Range
    Low 5.1200
    High 36.8500
  • Volume
    12,638
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 12.4
TimeVolumeTRDA
09:32 ET10312.4
09:43 ET50012.56
09:45 ET50012.27
09:48 ET39112.5
09:56 ET51112.475
10:06 ET50012.28
10:14 ET40012.35
10:15 ET20012.4
10:17 ET30012.5
10:19 ET80012.4
10:21 ET70012.41
10:24 ET187812.5
10:30 ET10012.49
10:57 ET20012.58
11:42 ET20012.49
11:49 ET10012.5
11:51 ET30012.54
12:05 ET10012.43
12:43 ET10012.69
01:55 ET10012.74
03:45 ET10012.98
03:59 ET88712.76
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesTRDA
Entrada Therapeutics Inc
395.5M
0.0x
---
United StatesNAUT
Nautilus Biotechnology Inc
354.0M
-5.4x
---
United StatesGLUE
Monte Rosa Therapeutics Inc
406.5M
-3.9x
---
United StatesHUMA
Humacyte Inc
359.5M
-19.0x
---
United StatesOMER
Omeros Corp
468.0M
-2.1x
---
United StatesPHAT
Phathom Pharmaceuticals Inc
354.1M
-2.4x
---
As of 2022-08-17

Company Information

Entrada Therapeutics, Inc. (Entrada) is a biopharmaceutical company aiming to transform the lives of patients by establishing a set of medicines, Endosomal Escape Vehicles (EEV) therapeutics, to engage intracellular targets that are considered inaccessible and undruggable. The Company's EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through its EEV Platform, Entrada is building a development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular diseases, immunology, oncology and diseases of the central nervous system. The Company's lead oligonucleotide programs include ENTR-601-44 targeting Duchenne muscular dystrophy (DMD), and a follow-on program targeting myotonic dystrophy type 1 (DM1). DMD is a monogenic X-linked disease caused by mutations in the DMD gene.

Contact Information

Headquarters
6 Tide StreetBOSTON, MA, United States 02210
Phone
857-305-1825
Fax
302-655-5049

Executives

Non-Executive Independent Chairman of the Board
Kush Parmar
President, Chief Executive Officer, Director
Dipal Doshi
Chief Financial Officer
Kory Wentworth
Chief Operating Officer
Nathan Dowden
Chief Scientific Officer
Natarajan Sethuraman

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$395.5M
Revenue (TTM)
---
Shares Outstanding
31.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
---
Book Value
$9.57
P/E Ratio
0.0x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.